ICIM – International College of Integrative Medicine – Report on Chelation Therapy Training
Dearborn, Michigan – September 16-17, 2026
Medical professionals have generally ignored the evidence that chelation therapy might improve the condition of many patients suffering with chronic diseases. Official bodies consistently favor phrasing like “insufficient evidence,” “not recommended,” or “usefulness is uncertain.” The Cleveland Clinic has offered cautious patient guidance, saying most healthcare providers view unapproved uses of chelation as misleading and even dangerous, because they can harm patients and delay evidence-based treatments that could help or even save their lives.
The federal Medicare program has long had a standing policy, calling EDTA chelation for atherosclerosis controversial, stating there is no widely accepted rationale for its claimed benefits, and that the therapy’s safety is questioned and its effectiveness has never been established by well-designed, controlled trials. As such, Medicare claims chelation is “experimental.” Heavy metals such as lead, mercury, cadmium, and arsenic can quietly accumulate in the body over time. These toxins may affect brain function, cardiovascular health, immune strength, and kidney performance. Conventional medicine treats acute heavy metal poisoning such as lead or mercury exposure. By reducing the toxic load of metals like lead, mercury, cadmium, and arsenic, chelation therapy supports better neurological, cardiovascular, and immune health. The Food and Drug Administration has approved DMSA for reduction of lead toxic body burden and EDTA for lead and certain cadmium conditions. The right chelator or combination depends on factors such as exposure history, documented toxic burden, health conditions, age, treatment tolerability, and treatment goals.
In this sea of fake news, this advanced training program – first offered by the International College of Integrative Medicine in 1991 – continues to present scientific and clinical evidence which, when adopted, could save millions suffering needlessly. Internal medicine and chelation expert Joseph T. Hickey, MD, recently chaired a two-day conference featuring senior physicians with dozens of years of expertise in helping patients to recover and resume vital, active lives.
The History Dictates the Best Treatment Protocols
First trained in 1983 to offer chelation and certified by the first specialty organization in 1985, I [of Humble, Texas] presented how observations and scientific studies since 1955 have guided the development of safe and effective protocols for patients young and old. My talk focused on the contribution made by toxic heavy metals – lead, mercury, arsenic, tin, others – in the origin and worsening of crippling diseases in every organ system. Interestingly, the 80 – 90% improvement routinely seen in patients with intravenous chelation is similarly found with oral chelation agents. [John Parks Trowbridge MD, FACAM – www.healthCHOICESnow.com]
Toxic Heavy Metals Create Most Degenerative Diseases
The increasingly exciting topic of environmental toxins and their relationship to human diseases was reviewed by internist and program chair Joseph T. Hickey, MD [of Hilton Head Island, South Carolina]. A prospective study by the Department of Veterans Affairs concluded that bone lead, but not blood lead, was associated with significant increase in all-cause mortality, an association that was more pronounced for cardiovascular disease [Weisskopf, MG, et al. Circulation. 2009]. A 2015 report suggested that the earlier study may have understated the true risk rather than overstated it. Numerous articles have shown that lead, arsenic, cadmium, and nickel accumulation decrease cognitive function and concurrent mercury makes these metals exponentially more toxic.
A surprising finding is that bismuth toxicity can masquerade as Alzheimer’s dementia, where its removal by chelation can reverse cognitive decline. Another obscure fact: for children and adults … orthopedic procedures, fractures, and even major injuries can release bone-accumulated toxic metals, resulting in depression, Parkinsonian patterns, and diminished mental function, all reversible by prompt chelation. Heavy metal impairment of insulin-degrading enzymes has been implicated in an increasing number of conditions, including development of gestational diabetes, high blood pressure, nephritis, and postpartum depression. This degradation has also been implicated in deposition of beta-amyloid at the blood-CSF barrier, suggesting that improvement can be achieved for some patients.
Dr. Hickey summarized recent understanding that a pregnant woman can lose up to 10% of her bone mass during the last trimester, with concomitant release of bound toxic heavy metals. A preventive program of calcium gluconate, magnesium glycinate, and zinc continued from the start of pregnancy can mitigate many of the commonly undiagnosed changes. He explained that fecal “challenged” [post-chelator] metal assessment appears to give more reliable determinations of toxic body burden. Cases of other neurological problems – ALS, peripheral neuropathy, MS, other CNS deterioration – often respond to appropriate chelation treatments. As always, investigation to find and remove or reduce a particular patient’s exposures can provide best results. [Joseph T. Hickey, MD, DABIM – www.drjosephhickey.com]
Chelators Are Well Understood and Safely Used
Chelation specialist and ICIM president Eric E. Born, DO [of Parchment, Michigan] gave an excellent review of common chelating agents, mechanisms of action, and usual ingredients in the IV solution. The chemistry of metal binding is not generally taught to physicians but examples are numerous: iron in hemoglobin, magnesium in chlorophyll, cobalt in vitamin B12, and more. Keys to understanding the treatment process for each different toxic metal chelator include route of administration, binding affinity for various toxic and physiologic metals, extracellular and intracellular distribution, transit of blood-brain barrier, excretory pathways, and possible as well as common side effects. Combinations of two or more chelating compounds have been explored to amplify the removal process.
Dr. Born included salient facts regarding use and precautions with EDTA, DTPA, DMSA, DMPS, d-Penicillamine, Deferoxamine, and Emeramide. He reviewed prechelation patient evaluation and testing to determine total body burden of toxic heavy metals as well as protocols for dosing and treatment frequency, concomitant nutritional support, and continuing monitoring. Effective chelation should always involve lifestyle changes, dietary guidelines, exercise programs, and attention to other patient issues, specifically kidney function and constipation. [Eric Born, DO, DABFM – www.bornintegrativemedicinemi.com]
Chelation Improvements Can Be Readily Documented
More attention to testing for toxic heavy metals and for patient status and conditions was presented by Jeannette Soriano, MD [of Banff, Alberta, Canada]. Comprehensive care of the patient is essential, to maximize results and minimize any adverse effects. Two Americans every minute have avoidable coronary events … 12% are diabetic … 115 million have prediabetes (metabolic syndrome, insulin resistance) that could respond well to chelation. Since toxic heavy metals can inactivate porphyrinogenic enzymes, Dr. Soriano advises urine porphyrin testing in combination with provocative urine testing or hair analysis, to gain a broader understanding of how any particular patient has become toxic. B-type Naturiuretic Peptide (BNP) can be an early marker of cardiomyopathy and monitor for improvement.
In-office Ankle-Brachial Index screening can help identify sclerotic arterial changes. Ultrafast CT “HeartScan” can provide a baseline calcium score in coronary arteries – and this might motivate patients to be more compliant with treatment. When needed, echocardiograms can assess ventricular and valvular dysfunction and duplex ultrasound can show undesirable changes in peripheral and carotid arteries. Heart rate variability testing is easy in-office, and decreased variability relates to increased mortality after acute myocardial infarction.
Scheduled follow-up testing and careful documentation of treatments administered is as important as noting clinical evidence supporting chelation plans and alterations. Her presentation reviewed supplementation to address comorbid conditions, nutrients depleted by chelation and by concurrent prescriptions, and items to enhance the effectiveness of treatment. Molybdenum is a component of metalloenzymes involved in liver detoxification and metabolism of sulfur-containing amino acids – and the need for supplementation can be readily overlooked. Dr. Soriano included review of essential fatty acids in addition to vitamins, minerals, and amino acids. [Jeannette Soriano, MD – www.drjsoriano.com]
Chelation Formulas Have Evolved Since 1955
Dr. Born returned to the lectern to provide extensive details on employing a safe and effective EDTA protocol in treating vascular disease. In devising the actual program, he offered several possible mechanisms of action for magnesium-disodium-EDTA. As an anticoagulant, there is a significant inhibition of the calcium-dependent function of a platelet glycoprotein. In vitro and in vivo animal studies have shown decalcification of pathologically deposited calcium in soft tissues such as blood vessels, valves, joints, and elsewhere – which Rudolf Virchow, “the father of modern pathology,” described as “metastatic” in that it was not confined to the skeletal compartment. Chelation treatments appear to move these abnormal deposits back into bone through decrease in ionized blood calcium stimulating the parathyroid hormone. This calcium reduction cascade might stabilize vulnerable plaques, reducing risk of acute thrombosis.
The antioxidant effect of EDTA is well known, having been added to foods (such as mayonnaise) since the early 1950s to retard their oxidation (rancid spoiling). Plasma ferric and cupric ions that promote oxidation of LDL cholesterol are reduced by EDTA. Lead inhibits nitric oxide formation – a signaling molecule acting as a vasodilator and anti-atherosclerotic – so removal by EDTA promotes physiologic function. Dr. Born concluded by discussing parameters of pediatric testing and treatment as well as guidelines and cautions for adult chelation programs.
Chelation Can Be Readily Introduced Into Medical Offices
Chelation specialist Robban A. Sica, MD [of Westport, Connecticut] extensively detailed practical applications of IV therapies, chelation and others. She emphasized that “metal binders” such as NAC, glutathione, chlorella, and cilantro, can attach to heavy metals but simply relocate them to other tissues, while chelating medications actually bind tightly to assist excretion into urine or bile. With regard to determining total body burden of toxic metals, serum levels ordered by conventional doctors only show acute exposure. RBC mineral analysis gives a 90-day average. Provoked and unprovoked urine metals can help understand retention of toxics.
Hair mineral analysis can be limited in that patients with apoE4 alleles do not secrete much into hair shafts. Dr. Sica noted distinct benefits of using chelation therapy during menopause and hormone replacement therapy.
The mechanics of constructing, manipulating, and administering various chelation solutions or parental forms are reviewed in great detail, an easy reference for nurses and doctors for years to come. She explained a number of pitfalls that could adversely affect patients, especially with regard to patient preparation, form of EDTA or other agent, osmolarity of solution, pH of solution, potassium and magnesium concentrations, rate of flow, combination of chelating agents, and frequency of treatments. Dr. Sica has a preference for Angiocath as less likely to infiltrate compared to butterfly needles. As with other specialists, she emphasized informed consent procedures, detailed documentation of each administration, and follow up assessment of results. [Robban A. Sica, MD, DHIM – www.DrSica.com]
Toxic Heavy Metals Are Pervasive and Deadly
The relationship of toxic heavy metals to oxidative stress and the diseases of aging was reviewed by chelation expert Robert S. Waters, MD [of Wisconsin Dells, Wisconsin]. A delightful surprise was the release of his superb comprehensive book, The Elements of Disease (full color illustrated edition, amazon https://amzn.to/3V8IRcU), offering insights into modern lifestyles and chronic degenerative changes. Relying on published studies, he offered data regarding treatment effects on urinary losses of metals, emphasizing continuing attention to zinc, magnesium, chromium, and copper. Heart Rate Variability assessment correlates with cardiac autonomic function and is associated with a number of metabolic abnormalities leading to early illness – including prediabetic insulin resistance – and death. Chelation therapy can improve autonomic dysfunction and glucose disruptions.
Dr. Waters explained that infusions of magnesium-EDTA produce marked increase in parathyroid hormone, and this pulsatile release might be fundamental to reducing atherosclerotic plaques and improving bone density. He reviewed ascorbic acid activities in the context of orthomolecular medicine, identified by Dr. Linus Pauling as the use of foods and nutraceuticals as therapies. Noting that dementia was rare 140 years ago, he questioned whether the industrial revolution has truly given us a better life.
One major issue is our increasing exposure to aluminum: food and beverages (especially packaging, cookware, emulsifying agents), drinking water, airborne dust, personal care products (antiperspirants and more), vaccines (especially for children), antacids, occupational exposure/industrial sites. Many beverages are packaged in aluminum cans, but a thin internal polymer lining is supposed to prevent the drink from reacting. Perhaps of more concern now is the variety of can-lining chemicals. Free radical production and alterations of biomolecules is widespread, including protein misfolding which is the causative basis of Parkinson’s Disease, Alzheimer’s Disease, neurodegenerative diseases, and more. Recent studies have shown an unequivocal relationship with autism, facts often disputed by pediatricians and government agencies. Age-dependent decline has been shown related to cross-linking of critical molecules, often producing autoimmunity. When iron is present as well, biochemical damage is amplified. Desferrioxamine is the preferred aluminum (and iron+3 and copper+3) chelator. Other contributing toxic heavy metals must be addressed as well, with EDTA, DMSA, others. [Robert S. Waters, MD – www.watersbiomed.com]
Stunning Improvements Beyond Cardiovascular Diseases
Program chair Joseph T. Hickey, MD, gave a most unusual review of disease patterns related to toxic heavy metal exposures beyond the cardiovascular changes. Fundamental to each of these are the inflammatory changes induced and amplified by toxic heavy metals, interfering with biochemical homeostasis in all tissues. As one example, he successfully treated a patient with fatigue and limiting symptoms due to myelodysplastic syndrome – one of a group of cancers in which blood cells in the bone marrow do not mature, and as a result, do not develop into healthy blood cells. White cells appeared suppressed by mercury, red cells suppressed by lead, and platelets suppressed by arsenic, and general suppression by toxic hydrocarbons, all related to cumulative lifetime environmental work exposures. Hematology consultation determined that he would be less likely to respond to bone marrow transplant. Dr. Hickey administered EDTA along with overall supportive care, achieving excellent resolution of the pancytopenia; he lived another 20 years and died from an unrelated health issue.
He presented other cases often considered untreatable, such as fibromyalgia, which affects over 5 million Americans, mostly women. His experience reducing toxic heavy metals in over 350 such patients showed 80 percent having 50 percent reduction in troublesome symptoms relating to neurotransmitters. Lead in bone has been implicated in toxicology during pregnancy and lactation, in soldiers exposed to weaponry, and many others. Dr. Hickey noted successful chelation treatment of those suffering with Gulf War Syndrome, reflex sympathetic dystrophy (regional pain syndrome), and various autoimmune conditions. He has warned for a dozen years of pervasive gadolinium toxicity (from MRI contrast injections), especially fibrosis symptoms in kidneys and skin. Reports have shown gadolinium concentration in brain tissues long after MRI studies. Discussion among the faculty revealed that numerous “non-cardiovascular” diseases have shown remarkable improvement with determination and reduction of toxic heavy metals and nutritional support.
The Future Is Now – Will Doctors Catch Up?
Integrative medicine has emerged in response to growing recognition that chronic diseases often involve interacting nutritional, metabolic, environmental, and lifestyle factors that may not be fully addressed by conventional symptom-focused care. Despite longstanding resistance from mainstream medicine — particularly toward concepts such as clinically significant heavy-metal toxicity — research and clinical experience have increasingly encouraged broader investigation of environmental exposures, prevention, and individualized approaches to chronic illness. Chelation therapy has a centerpiece role in addressing the greatest number of puzzling degenerative diseases.
________________________
The International College of Integrative Medicine teaches the latest research in preventive, alternative, and innovative treatments. Through our semiannual conferences and advanced-level training, we seek to fulfill our mission of providing physicians with a comprehensive understanding of utilizing more than just drugs or surgical procedures in the holistic care of patients.
Active members have graduated from an accredited institution offering doctoral degrees: MD, DO, DDS, DMD, DPM, DVM, DC, ND, PharmD, and RPh. Further, associate members include those earning PhD, ScD, DrPH, DOM, PA, NP, and RN. Affiliate membership is available for those formally involved in healthcare, such as PA, NP, LMT, PT, nutritional counselors, colon therapists, iridologists, and so on.
Browse our website at www.icimed.com for details on general conferences featuring leading experts on current topics and for advanced training sessions. Our executive director is Audra Vaccarella, DC, MBA, BSc. Join us at our spring meeting in Charlotte, North Carolina, March 18-20, 2027. We’d love to introduce you to our world! Contact ICIM at 414-312-ICIM (4246), or Box 271, Bluffton, Ohio 45817, or info@icimed.com.
Dr. Trowbridge is a past president of ICIM, coauthor of several books including Bantam Books’ 1986 classic reference The Yeast Syndrome, and producer of over five dozen CDs/DVDs on integrative medicine topics.










0 Comments